AbbVie
Prescription Drugs · Immunology & Inflammation Therapeutics

AbbVie revenue, results and funding

AbbVie filed revenue of $61.2B for 2025.

Data updated Nov 19, 2026 · Back to the company report
$61.2BRevenue, 2025
$4.2BNet income, 2025
ABBVNew York Stock Exchange

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_DIVIDENDSLANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBTLANG_CR_S_M_ACQUISITIONS
2025$61.2B$4.2B$134B$3.6B$2.4B$11.7B$980M$1.2B$955M$9.1B$15.1B$5.2B$64.5B$204M
2024$56.3B$4.3B$135.2B$4.1B−$570M$11B$1.7B$974M$911M$12.8B$9.1B$5.5B$66.8B$17.5B
2023$54.3B$4.9B$134.7B$4.7B$1.4B$10.5B$2B$777M$747M$7.7B$12.8B$12.8B$59.2B$0
2022$58.1B$11.8B$138.8B$3B$1.6B$10B$1.5B$695M$671M$6.5B$18.1B$9.2B$63.1B$255M
2021$56.2B$11.5B$146.5B$3.6B$1.4B$9.3B$934M$787M$692M$6.9B$17.9B$9.7B$76B$525M
2020$45.8B$4.6B$150.6B$1.7B−$1.2B$7.7B$978M$798M$753M$6.4B$11.4B$8.4B$84.9B$38.3B
2019$33.3B$7.9B$89.1B$1.4B$544M$6.4B$629M$552M$430M$6.4B$13B$39.9B$67.2B$0
2018$32.8B$5.7B$59.4B–−$490M$5.6B$12B$638M$421M$10.3B$6.4B$7.3B–$0
2017$28.2B$5.3B$70.8B$1.7B$2.4B$4.1B$1.4B$529M$365M$5B$9.5B$9.3B–$0
2016$25.6B$6B$66.1B$3.6B$1.9B$3.7B$6B$479M$353M$4.4B$9.3B$5.1B–$2.5B
2015$22.9B$5.1B$53.1B$1.1B$1.5B$3.3B$7.6B$532M$282M$4.3B$7.5B$8.4B–$11.5B
2014$20B$1.8B$27.5B$498M$595M$2.7B$665M$612M$241M$3.3B$3.4B$8.3B–$622M
2013$18.8B–$29.2B$1.3B$1.2B$2.6B$320M$491M$212M$2.9B$5.7B$9.6B–$405M
2012$18.4B–$27B–$450M––$333M$187M$2.8B$5.8B$5.9B–$688M
2011$17.4B–––$235M––$356M$163M$2.6B$3.6B$27M–$273M
Sources: SEC

How to cite

AbbVie, Financials. Alion, Nov 19, 2026. https://alion.io/company/abbvie/financials

.json · .md · CC BY-SA 4.0